TP-030-2

• UNSPSC Description:

  TP-030-2 is a RIPK1 inhibitor (human Ki=0.43 nM; mouse IC50=100 nM)[1][2].

• Target Antigen:

  RIP kinase; Ser/Thr Protease

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/tp-030-2.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C1C2=NN(CC3=CC=CC=C3)C(Br)=C2CCN1[C@@H]4C(N(C5=CC=CC=C5OC4)C)=O

• Molecular Weight:

  481.34

• References & Citations:

  [1]Yoshikawa M, et al. Discovery of 7-Oxo-2,4,5,7-tetrahydro-6 H-pyrazolo[3,4- c]pyridine Derivatives as Potent, Orally Available, and Brain-Penetrating Receptor Interacting Protein 1 (RIP1) Kinase Inhibitors: Analysis of Structure-Kinetic Relationships. J Med Chem. 2018 Mar 22;61(6):2384-2409.|[2]https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/TP-030-2

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2095514-84-2